Crossmark

A boost or a redundancy? on the value of combination of androgen receptor signal inhibitor and PARP inhibitor for advanced prostate cancer

Published Online: 2024-09-30

Authors

Wang, Qihao

Ye, Jianjun

Zheng, Lei

Tu, Xiang

Zeng, Hao

Bao, Yige https://orcid.org/0000-0003-4002-5467
Wei, Qiang
License Information

Text and Data Mining valid from 2024-09-30

Version of Record valid from 2024-09-30
More Information

Article History

Received: 2 June 2024

Accepted: 17 September 2024

First Online: 30 September 2024

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current